Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older
← catalyst calendarNCT05844449 · readout in 1,076 d
Sponsored by Vertex Pharmaceuticals Incorporated (industry) · VRTX — their whole pipeline →.
Phase
Phase 3
Status
Enrolling by invitation
Study type
Interventional
Design
Na · None · Treatment
Enrollment
174estimated
Sites
37
Countries
Australia, Canada, France +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-08-11 | actual | When the study began enrolling |
| Primary completion | 2029-07-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-07-30 | estimated | The whole study's end, after follow-up |
| First posted | 2023-05-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Cystic Fibrosis
Intervention
- Drug: VNZ/TEZ/D-IVA — also filed as VX-121/VX-661/VX-561, VX-121/VX-661/CTP-656, vanzacaftor/tezacaftor/deutivacaftor
Primary outcomes
what the primary-completion date above is the date OFPart A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs)
measured From Baseline up to Week 100
Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs)
measured From Baseline up to Week 196
Permalink · VRTX's whole pipeline · Catalyst calendar · Every registered study · What changed